Down syndrome maternal serum screening in patients with renal disease

被引：7
作者：
Benachi, Alexandra [2 ]
Dreux, Sophie [1 ]
Kaddioui-Maalej, Sahar [2 ]
Czerkiewicz, Isabelle [1 ]
Fakhouri, Fadi [3 ]
Thervet, Eric [4 ]
Muller, Francoise [1 ]
机构：
[1] Univ Paris Ile France Ouest, Dept Biochem, Hop Robert Debre, Assistance Publ Hop Paris, F-75019 Paris, France
[2] Univ Paris 05, Dept Obstet & Gynecol, Hop Necker Enfants Malad, Assistance Publ Hop Paris, Paris, France
[3] Assistance Publ Hop Paris, Dept Nephrol, Hop Necker Enfants Malad, Paris, France
[4] Assistance Publ Hop Paris, Dept Renal Transplantat, Hop Necker Enfants Malad, Paris, France
来源：
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY | 2010年 / 203卷 / 01期
关键词：
pregnancy; prenatal diagnosis; renal failure; trisomy; 21; NUCHAL TRANSLUCENCY; GONADOTROPIN; PREGNANCY; CREATININE; MARKER;
D O I：
10.1016/j.ajog.2010.01.080
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
OBJECTIVE: The objective of the study was to determine the value of maternal serum Down syndrome screening in patients affected by renal disease. STUDY DESIGN: A study group of 54 pregnant women with renal diseases defined before pregnancy, was compared with a control group of 108 patients matched for maternal age, maternal weight, smoking status, and gestational age. Maternal serum markers (free beta-human chorionic gonadotropin [hCG], total hCG, alpha-fetoprotein) expressed in multiple of median and maternal renal function markers (creatinine, beta 2-microglobulin, alpha 1-microglobulin) were assayed. RESULTS: The percentage of patients in the Down syndrome at-risk group (>1:250) using free beta-hCG was significantly higher (P < .02) in the renal disease group (48%) than in the control group (12%). No significant difference was observed for total hCG (25% vs 15%). CONCLUSION: Down syndrome screening using free beta-hCG is not applicable in patients with renal disease whatever the maternal serum creatinine and can be used with caution when total hCG is used.
引用
收藏
页码：60.e1 / 60.e4
页数：4
相关论文
共 50 条
  • [21] Down syndrome maternal serum marker screening after 18 weeks of gestation: a countrywide study
    Dreux, Sophie
    Nguyen, Claire
    Czerkiewicz, Isabelle
    Schmitz, Thomas
    Azria, Elie
    Foure, Marc-Antoine
    Muller, Francoise
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (05) : 397.e1 - 397.e5
  • [22] Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18
    Akbas, SH
    Özben, T
    Alper, Ö
    Ugur, A
    Yücel, G
    Lüleci, G
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (06) : 487 - 490
  • [23] PRENATAL DETECTION OF X-LINKED ICHTHYOSIS BY MATERNAL SERUM SCREENING FOR DOWN-SYNDROME
    BARTELS, I
    CAESAR, J
    SANCKEN, U
    PRENATAL DIAGNOSIS, 1994, 14 (03) : 227 - 229
  • [24] 'Dual positivity' for neural tube defects and Down syndrome at maternal serum screening: Gestational outcome
    Zanini, R
    Tarantini, M
    Cerri, V
    Jacobello, C
    Bellotti, D
    Lancetti, S
    Scalchi, S
    Groli, C
    Bianchi, UA
    FETAL DIAGNOSIS AND THERAPY, 1998, 13 (02) : 106 - 110
  • [25] 1ST TRIMESTER MATERNAL SERUM ALPHA-FETOPROTEIN SCREENING FOR DOWN-SYNDROME AND OTHER ANEUPLOIDIES
    WENGER, D
    MINY, P
    HOLZGREVE, W
    FUHRMANN, W
    ALTLAND, K
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1990, : 89 - 90
  • [26] The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome
    Christiansen, M
    Hogdall, EV
    Larsen, SO
    Hogdall, C
    PRENATAL DIAGNOSIS, 2002, 22 (05) : 385 - 387
  • [27] Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome
    Muller, F
    Dreux, S
    Lemeur, A
    Sault, C
    Desgrès, J
    Bernard, MA
    Giorgetti, C
    Lemay, C
    Mirallié, S
    Beauchet, A
    PRENATAL DIAGNOSIS, 2003, 23 (13) : 1073 - 1076
  • [28] Second-trimester Down syndrome maternal serum screening in twin pregnancies: impact of chorionicity
    Muller, FO
    Dreux, S
    Dupoizat, H
    Uzan, S
    Dubin, MF
    Oury, JF
    Dingeon, B
    Dommergues, M
    PRENATAL DIAGNOSIS, 2003, 23 (04) : 331 - 335
  • [29] First-Trimester Screening for Down Syndrome with Serum Sampling at Different Gestational Ages: The Effect on Screening Performance
    Engels, Melanie A. J.
    Twisk, Jos W. R.
    Blankenstein, Marinus A.
    van Vugt, John M. G.
    FETAL DIAGNOSIS AND THERAPY, 2014, 36 (04) : 293 - 298
  • [30] Impact of antiphospholipid biology in maternal Down syndrome screening
    Brochet, Christine
    Morin, Nathalie
    Coudert, Mathieu
    Vauthier-Brouzes, Daniele
    Costedoat-Chalumeau, Nathalie
    Bernard, Maguy
    PRENATAL DIAGNOSIS, 2009, 29 (05) : 481 - 488
12345